The Council announced its decision on Monday after facing a wave of criticism. The public hearing will receive suggestions on the regulation of the matter
or Federal Council of Medicine (FCM) decided to suspend the resolution that limited the prescription of cannabidiolcompost obtained from the plant cannabis sativa (marijuana), after an extraordinary meeting on Monday 24th. The CFM changed the rule ten days ago and faced strong criticism from specialists and relatives of patients who depend on the compound.
In a public note, the board clarified that the terms of the 14 October rule are suspended, “the decision to indicate the use of cannabidiol in the presentations authorized by the National Health Supervisory Agency (Anvisa) being under the responsibility of the physician” .
Last week, the CFM had already done so decided to re-discuss the topic through a public consultation. Monday’s position reaffirmed the possibility of popular participation to receive contributions on the subject. “Stakeholders will have 60 days – from 24 October to 23 December 2022 – to present their suggestions through an electronic platform developed by CFM”.
The interested parties, having informed the Board, can take a position on each of the articles and paragraphs of the CFM Resolution no. 2,324/2022, and must provide some identification data. “After this step, the user will automatically connect to the system, becoming able to submit their proposals. The information, which will serve as an aid to the CFM, will be treated according to criteria of confidentiality and anonymity”.
Norma faced criticism
Published on October 14 in the Official Gazette (DOU), the CFM standard was met with criticism from experts.
With the rule now suspended, the council authorized the medical profession to prescribe the product only for the treatment of childhood and adolescent epilepsies associated with Dravet and Lennox-Gastaut syndromes and the Tuberous Sclerosis Complex – and only in cases where the patient it has not shown good results with conventional treatments.
For the Brazilian Cannabis Association Esperança Support (Abrace), the resolution was controversial and the “fences interfere with the execution of the treatment of several patients and prohibit the dissemination of knowledge about cannabis important to doctors and patients”, as reported in occasion of the disclosure of the ordinance.
The main controversy highlighted by the resolution’s critics was the fact that there are already 18 medical cannabis products approved in Brazil by the National Health Surveillance Agency (Anvisa), including one drug indicated for the treatment of stiffness associated with multiple sclerosis. . / COLLABORATE FABIANA CAMBRICOLI, ROBERTA JANSEN AND MARCO ANTÔNIO CARVALHO
+The best content in your email for free. Choose your favorite Earth Newsletter. Click here!
Source: Terra
Benjamin Smith is a fashion journalist and author at Gossipify, known for his coverage of the latest fashion trends and industry insights. He writes about clothing, shoes, accessories, and runway shows, providing in-depth analysis and unique perspectives. He’s respected for his ability to spot emerging designers and trends, and for providing practical fashion advice to readers.
